AI Article Synopsis

  • Researchers developed a microbiome-based diagnostic test for inflammatory bowel disease (IBD) by analyzing 5,979 fecal samples, identifying significant bacterial alterations related to IBD.* ! * The study created diagnostic models using ten bacterial species for ulcerative colitis and nine for Crohn's disease, achieving high accuracy (areas under the curve >0.90) in distinguishing IBD from healthy controls.* ! * A new multiplex droplet digital PCR test was also developed, which outperformed the standard fecal calprotectin test, indicating the potential for a noninvasive multibacteria biomarker panel in IBD diagnosis.* !

Article Abstract

Despite recent progress in our understanding of the association between the gut microbiome and inflammatory bowel disease (IBD), the role of microbiome biomarkers in IBD diagnosis remains underexplored. Here we developed a microbiome-based diagnostic test for IBD. By utilization of metagenomic data from 5,979 fecal samples with and without IBD from different geographies and ethnicities, we identified microbiota alterations in IBD and selected ten and nine bacterial species for construction of diagnostic models for ulcerative colitis and Crohn's disease, respectively. These diagnostic models achieved areas under the curve >0.90 for distinguishing IBD from controls in the discovery cohort, and maintained satisfactory performance in transethnic validation cohorts from eight populations. We further developed a multiplex droplet digital polymerase chain reaction test targeting selected IBD-associated bacterial species, and models based on this test showed numerically higher performance than fecal calprotectin in discriminating ulcerative colitis and Crohn's disease from controls. Here we discovered universal IBD-associated bacteria and show the potential applicability of a multibacteria biomarker panel as a noninvasive tool for IBD diagnosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11645270PMC
http://dx.doi.org/10.1038/s41591-024-03280-4DOI Listing

Publication Analysis

Top Keywords

inflammatory bowel
8
bowel disease
8
ibd diagnosis
8
bacterial species
8
diagnostic models
8
ulcerative colitis
8
colitis crohn's
8
crohn's disease
8
ibd
7
noninvasive microbiome-based
4

Similar Publications

Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.

Therap Adv Gastroenterol

December 2024

Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Via Giustiniani, 2, Padua 35128, Italy.

Crohn's disease (CD) is a chronic, complex inflammatory disorder of the gastrointestinal tract that presents significant therapeutic challenges. Despite the availability of a wide range of treatments, many patients experience primary non-response, secondary loss of response, or adverse events, limiting the overall effectiveness of current therapies. Clinical trials often report response rates below 60%, partly due to stringent inclusion criteria.

View Article and Find Full Text PDF

Clostridium butyricum, a future star in sepsis treatment.

Front Cell Infect Microbiol

December 2024

Medical Laboratory, Kunming Children's Hospital, Children's Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China.

Sepsis is a systemic inflammatory response syndrome of multiorgan failure caused by dysregulation of the host response to infection and is a major cause of death in critically ill patients. In recent years, with the continuous development of sequencing technology, the intestinal microecology of this disease has been increasingly studied. The gut microbiota plays a host-protective role mainly through the maintenance of normal immune function and the intestinal barrier.

View Article and Find Full Text PDF

Crohn's disease (CD) is a complex inflammatory bowel disease resulting from an interplay of genetic, microbial, and environmental factors. Cell-type-specific contributions to CD etiology and genetic risk are incompletely understood. Here we built a comprehensive atlas of cell-type- resolved chromatin accessibility comprising 557,310 candidate cis-regulatory elements (cCREs) in terminal ileum and ascending colon from patients with active and inactive CD and healthy controls.

View Article and Find Full Text PDF

Current Approaches to Ulcerative Colitis Management: A Comprehensive Overview of Methodologies and Treatments.

Infect Disord Drug Targets

December 2024

Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.

Ulcerative colitis is a chronic, idiopathic, inflammatory condition affecting the colon, primarily impacting individuals aged 30 to 40. It typically begins in the rectum and gradually progresses to the proximal regions of the colon, characterized by recurrent and remitting mucosal inflammation. Ulcerative colitis is categorized under inflammatory bowel disease, which encompasses various gastrointestinal tract disorders, but its underly-ing pathophysiology remains unclear.

View Article and Find Full Text PDF

Background/aims: Portal vein thrombosis (PVT) frequently occurs in patients with inflammatory bowel disease (IBD), particularly when influenced by factors such as abdominal infections, IBD flare-ups, or surgical procedures. The implications of PVT range from immediate issues such as intestinal ischemia to long-term concerns including portal hypertension and its complications. However, there is a notable gap in comprehensive studies on PVT in IBD, especially with the increasing incidence of IBD in Asia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!